Ricardo Titze-de-Almeida, Catherine David & Simoneide Souza Titze-de-Almeida. Pharmaceutical Research. 2017.
“KRAS-LODER made KRAS a druggable anticancer target. New drugs also targeting this oncogene are now in test and may represent future competitors of KRAS-LODER. KRAS-LODER is the only RNAi-based drug that provides a sustained release of siRNA into the tumor region thanks to a well-known biodegradable PLGA polymer, approved by FDA for drug delivery.
This siRNA represents a hopeful strategy against advanced pancreatic cancer…. Taking the aggressive behavior of pancreatic tumor cells, KRAS-LODER is a promising anticancer therapy.
Results of a phase 1/2a was positive in a relatively small number of patients, so we must wait for an ongoing phase 2 study that is testing KRAS-LODER (2.8 mg) plus standard chemotherapy for patients with unresectable advanced pancreatic cancer”